JP2020063225A - Wrinkle improving composition and wrinkle improving skin cosmetic - Google Patents
Wrinkle improving composition and wrinkle improving skin cosmetic Download PDFInfo
- Publication number
- JP2020063225A JP2020063225A JP2018197701A JP2018197701A JP2020063225A JP 2020063225 A JP2020063225 A JP 2020063225A JP 2018197701 A JP2018197701 A JP 2018197701A JP 2018197701 A JP2018197701 A JP 2018197701A JP 2020063225 A JP2020063225 A JP 2020063225A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- wrinkle
- improving
- composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 230000037303 wrinkles Effects 0.000 title claims abstract description 84
- 239000002537 cosmetic Substances 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 110
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 46
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 46
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 46
- 229940010454 licorice Drugs 0.000 claims abstract description 46
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 21
- 239000009538 yokuinin Substances 0.000 claims description 20
- 241000480037 Argyrosomus japonicus Species 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 23
- 241000544270 Angelica acutiloba Species 0.000 abstract description 4
- 244000167230 Lonicera japonica Species 0.000 abstract description 4
- 235000017617 Lonicera japonica Nutrition 0.000 abstract description 4
- 230000003712 anti-aging effect Effects 0.000 abstract description 3
- 244000077995 Coix lacryma jobi Species 0.000 abstract 2
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 206010040954 Skin wrinkling Diseases 0.000 description 119
- 241000202807 Glycyrrhiza Species 0.000 description 45
- 210000003491 skin Anatomy 0.000 description 41
- 239000011049 pearl Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 27
- 238000009472 formulation Methods 0.000 description 26
- 238000000605 extraction Methods 0.000 description 24
- 229930014626 natural product Natural products 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 15
- 239000002994 raw material Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 239000003513 alkali Substances 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 241000252229 Carassius auratus Species 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 6
- 108010014258 Elastin Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 210000002469 basement membrane Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 108010006161 conchiolin Proteins 0.000 description 6
- 229920002549 elastin Polymers 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000237536 Mytilus edulis Species 0.000 description 5
- -1 aliphatic alcohols Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 235000011201 Ginkgo Nutrition 0.000 description 4
- 244000194101 Ginkgo biloba Species 0.000 description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 210000001626 skin fibroblast Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000490567 Pinctada Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000004141 dimensional analysis Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 235000020638 mussel Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 241000759834 Aucuba japonica Species 0.000 description 2
- 241000209205 Coix Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 241001570521 Lonicera periclymenum Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229950004959 sorbitan oleate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000004162 Claudin-1 Human genes 0.000 description 1
- 108090000600 Claudin-1 Proteins 0.000 description 1
- 241000382825 Cristaria plicata Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241001331480 Hyriopsis schlegelii Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000222418 Lentinus Species 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000237524 Mytilus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000490568 Pinctada fucata Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010988 intraclass correlation coefficient Methods 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、天然物由来成分を組み合わせてなるしわ改善用組成物、および当該組成物を含有するしわ改善用皮膚化粧料に関するものである。 TECHNICAL FIELD The present invention relates to a wrinkle-improving composition obtained by combining ingredients derived from a natural product, and a wrinkle-improving skin cosmetic containing the composition.
皮膚の表皮および真皮は、表皮細胞、線維芽細胞ならびにこれらの細胞の外にあって皮膚構造を支持するコラーゲン、エラスチン等の細胞外マトリックスにより構成されている。若い皮膚においては線維芽細胞の増殖は活発であり、線維芽細胞、細胞外マトリックス成分等の皮膚組織の相互作用が恒常性を保つことにより柔軟性、弾力性等が確保され、肌は外見的にも張りや艶がある状態に維持される。 The epidermis and dermis of the skin are composed of epidermal cells, fibroblasts, and extracellular matrices such as collagen and elastin that are outside these cells and support the skin structure. Proliferation of fibroblasts is active in young skin, and by maintaining the homeostasis of interactions between skin tissue such as fibroblasts and extracellular matrix components, flexibility and elasticity are secured, and the skin is It is also maintained in tension and luster.
ところが、紫外線の照射、空気の著しい乾燥、過度の皮膚洗浄等、ある種の外的因子の影響があったり、加齢が進んだりすると、細胞外マトリックスの主要構成成分であるコラーゲン、エラスチン等の産生量が減少するとともに、分解や変質を引き起こす。その結果、皮膚の柔軟性や弾力性が低下し、肌は張りや艶を失い、しわ等の老化症状を呈するようになる。 However, when it is affected by some external factors such as irradiation with ultraviolet rays, extremely dry air, excessive skin washing, or when aging progresses, collagen, elastin, etc., which are the main components of the extracellular matrix, Its production decreases and causes decomposition and deterioration. As a result, the flexibility and elasticity of the skin are reduced, the skin loses its tension and luster, and aging symptoms such as wrinkles are exhibited.
しわの形成を抑制する成分や、しわを改善する成分として、多種多様なものが提案されているが（例えば、特許文献１〜２参照）、新たな有効成分に対する需要は依然として大きいのが現状である。このような中、しわ改善評価の基準化も進められている（非特許文献１〜２参照）。 A wide variety of components have been proposed as components for suppressing the formation of wrinkles and components for improving wrinkles (see, for example, Patent Documents 1 and 2), but at present the demand for new active ingredients is still great. is there. Under such circumstances, standardization of wrinkle improvement evaluation is also underway (see Non-Patent Documents 1 and 2).
本発明は、しわ改善作用に優れた新規な組成物、および当該組成物を含有する抗老化用皮膚化粧料を提供することを目的とする。 An object of the present invention is to provide a novel composition having an excellent effect of improving wrinkles, and an anti-aging skin cosmetic composition containing the composition.
上記目的を達成するために本発明者らが鋭意検討した結果、甘草葉抽出物を、所定の天然物由来成分と組み合わせることで、しわ改善作用により一層優れたものとなることを見出し、本発明を完成させるに至った。 As a result of intensive studies by the present inventors in order to achieve the above object, it was found that the licorice leaf extract was combined with a predetermined natural product-derived component to be more excellent in the wrinkle-improving action, and the present invention Has been completed.
具体的には、本発明は以下のとおりである。
〔１〕 甘草葉抽出物と、
トウキ抽出物、キンギンカ抽出物、ヨクイニン抽出物および真珠タンパク質加水分解物の４種のうち少なくとも１種と
を組み合わせてなることを特徴とするしわ改善用組成物。
〔２〕 前記トウキ抽出物、前記キンギンカ抽出物、前記ヨクイニン抽出物および前記真珠タンパク質加水分解物の４種を組み合わせることを特徴とする〔１〕に記載のしわ改善用組成物。
〔３〕 〔１〕または〔２〕に記載のしわ改善用組成物を含有することを特徴とするしわ改善用皮膚化粧料。
Specifically, the present invention is as follows.
[1] A licorice leaf extract,
A composition for improving wrinkles, which is characterized by being combined with at least one kind of four kinds of Touki extract, Kingfish extract, Yokuinin extract and pearl protein hydrolyzate.
[2] The wrinkle-improving composition according to [1], characterized in that four kinds of the Touki extract, the Kingfish extract, the Yokuinin extract, and the pearl protein hydrolyzate are combined.
[3] A wrinkle-improving skin cosmetic comprising the wrinkle-improving composition according to [1] or [2].
本発明によれば、甘草葉抽出物を所定の天然物由来成分と組み合わせることにより、しわ改善作用に優れた新規な組成物、および当該組成物を含有する抗老化用皮膚化粧料を提供することができる。 According to the present invention, by providing a licorice leaf extract in combination with a predetermined natural product-derived component, a novel composition having an excellent wrinkle-improving effect, and an anti-aging skin cosmetic composition containing the composition are provided. You can
以下、本発明の実施の形態について説明する。
本発明の一実施形態に係るしわ改善用組成物は、甘草葉抽出物と、トウキ抽出物、キンギンカ抽出物、ヨクイニン抽出物および真珠タンパク質加水分解物の４種のうち少なくとも１種とを組み合わせてなるものである。
また、本発明の他の一実施形態に係るしわ改善用皮膚化粧料は、上記しわ改善用組成物を含有するものである。
Hereinafter, embodiments of the present invention will be described.
A composition for improving wrinkles according to an embodiment of the present invention is a combination of a licorice leaf extract and at least one of four types of a Japanese lentinus extract, a goldfish extract, a yokinin extract and a pearl protein hydrolyzate. It will be.
A wrinkle-improving skin cosmetic composition according to another embodiment of the present invention contains the above-mentioned wrinkle-improving composition.
ここで、本実施形態において「抽出物」には、上記植物を抽出原料として得られる抽出液、当該抽出液の希釈液若しくは濃縮液、当該抽出液を乾燥して得られる乾燥物、またはこれらの粗精製物若しくは精製物のいずれもが含まれる。 Here, in the present embodiment, the "extract" means an extract obtained by using the plant as an extraction raw material, a dilute solution or a concentrated solution of the extract, a dried product obtained by drying the extract, or a product thereof. Both a crude product and a purified product are included.
本実施形態に係るしわ改善用組成物は、必須成分である甘草葉抽出物の作用を利用して、しわ改善効果を発揮することができる。
本発明者らは、甘草葉抽出物の有効性をより高めるべく、甘草葉抽出物と組み合わせる有効成分を探索した結果、トウキ抽出物、キンギンカ抽出物、ヨクイニン抽出物および真珠タンパク質加水分解物の４種のうち少なくとも１種と組み合わせることにより、甘草葉抽出物によるしわ改善効果をより効果的に発揮させることができることを見出し、本実施形態の構成に至ったものである。
以下、本実施形態について詳細に説明する。
The wrinkle-improving composition according to the present embodiment can exhibit a wrinkle-improving effect by utilizing the action of the licorice leaf extract which is an essential component.
In order to further enhance the effectiveness of the licorice leaf extract, the present inventors have searched for an active ingredient to be combined with the licorice leaf extract, and as a result, 4 of the extract of Touki, King ginkgo extract, Yokuinin extract and pearl protein hydrolyzate have been investigated. The present inventors have found that the wrinkle-reducing effect of the licorice leaf extract can be more effectively exhibited by combining with at least one of the above-mentioned species, and have reached the constitution of the present embodiment.
Hereinafter, this embodiment will be described in detail.
〔甘草葉抽出物，トウキ抽出物，キンギンカ抽出物，ヨクイニン抽出物の製造〕
本実施形態において、甘草葉抽出物、トウキ抽出物、キンギンカ抽出物およびヨクイニン抽出物を製造するために使用する抽出原料は、甘草、トウキ（学名：Angelica acutiloba Kitagawa）、キンギンカ（学名：Lonicera japonica Thunberg．）、およびヨクイニン（生薬名）である。
[Production of Licorice Leaf Extract, Touki Extract, Goldfish Extract, Yokuinin Extract]
In the present embodiment, the extraction raw materials used for producing the licorice leaf extract, the Japanese laurel extract, the King Ginka extract and the Yukuinin extract are licorice, Toki (scientific name: Angelica acutiloba Kitagawa), King ginka (scientific name: Lonicera japonica Thunberg). .) And Yokuinin (crude drug name).
甘草は、マメ科グリチルリーザ（Glycyrrhiza）属に属する多年生草本である。甘草には、グリチルリーザ・グラブラ（Glychyrrhiza glabra）、グリチルリーザ・インフラータ（Glychyrrhiza inflata）、グリチルリーザ・ウラレンシス（Glychyrrhiza uralensis）、グリチルリーザ・アスペラ（Glychyrrhiza aspera）、グリチルリーザ・ユーリカルパ（Glychyrrhiza eurycarpa）、グリチルリーザ・パリディフロラ（Glychyrrhiza pallidiflora）、グリチルリーザ・ユンナネンシス（Glychyrrhiza yunnanensis）、グリチルリーザ・レピドタ（Glychyrrhiza lepidota）、グリチルリーザ・エキナタ（Glychyrrhiza echinata）、グリチルリーザ・アカンソカルパ（Glychyrrhiza acanthocarpa）等、様々な種類のものがあり、これらのうち、いずれの種類の甘草を抽出原料として使用してもよいが、特にグリチルリーザ・グラブラ（Glychyrrhiza glabra）、グリチルリーザ・ウラレンシス（Glychyrrhiza uralensis）、およびグリチルリーザ・インフラータ（Glychyrrhiza inflata）を抽出原料として使用することが好ましい。 Licorice is a perennial herb belonging to the genus Glycyrrhiza of the legume family. For licorice, Glychyrrhiza glabra, Glychyrrhiza inflata, Glychyrrhiza uralensis, Glychyrrhiza pallah, lypa, Glychyrrhiza inflata. ), Glychyrrhiza yunnanensis, Glychyrrhiza lepidota, Glychyrrhiza echinata, Glychyrrhiza acanthocarpa, and many other types of these, including Glychyrrhiza acanthocarpa. Licorice may be used as an extraction raw material, but especially Glychyrrhiza glabra and Glychyrrhiza uralen sis) and Glychyrrhiza inflata are preferably used as the extraction raw material.
本実施形態において、抽出原料として使用する甘草の構成部位は、葉部である。ここで、甘草は、その根部が古代より薬用または甘味料の原料として利用され、グリチルリチンその他の有用成分が含有されていることが知られており、一般に「甘草」といえばその根部を指す。しかし、本実施形態においては、根部を利用した後の残部に着目した結果、甘草の葉部からの抽出物を用いることとしたものである。なお、根部に含まれるグリチルリチンその他の有用成分は、甘草の葉部には含有されていない。 In the present embodiment, the constituent part of licorice used as the extraction raw material is the leaf part. Here, licorice has been used since ancient times as a raw material for medicinal or sweeteners, and it is known that glycyrrhizin and other useful ingredients are contained therein. Generally speaking, "licorice" refers to the root. However, in the present embodiment, as a result of paying attention to the remaining portion after the root portion is used, the extract from the licorice leaf portion is used. Glycyrrhizin and other useful components contained in the root portion are not contained in the licorice leaf portion.
トウキ（Angelica acutiloba Kitagawa）は、日本原産の植物であるセリ科シシウド属に属する多年草であり、これらの地域から容易に入手することができる。抽出原料として使用し得るトウキの構成部位としては、例えば、葉部、茎部、花部、果実部、根部、根茎部、地上部、またはこれらの混合物が挙げられるが、好ましくは根部である。 Touki (Angelica acutiloba Kitagawa) is a perennial plant belonging to the genus Cisiu, which is a plant native to Japan, and can be easily obtained from these regions. Examples of the constituent parts of Touki that can be used as an extraction raw material include leaves, stems, flowers, fruits, roots, rhizomes, aerial parts, and a mixture thereof, but the roots are preferable.
キンギンカ（Lonicera japonica Thunberg.，別名：スイカズラ）は、スイカズラ科スイカズラ属に属する常緑つる性木本であり、日本全国、東アジア一帯等に自生しており、これらの地域から容易に入手することができる。抽出原料として使用し得る部位としては、例えば、葉部、茎部、花部、蕾部、果実部、果皮部、果核部、地上部、全草またはこれらの混合物等が挙げられるが、好ましくは葉部、茎部、花部または蕾部である。 Goldinka (Lonicera japonica Thunberg., Also known as honeysuckle) is an evergreen vine that belongs to the honeysuckle genus Lonicera, which grows nationwide in Japan and throughout East Asia, and can be easily obtained from these areas. it can. Examples of the site that can be used as an extraction raw material include leaves, stems, flowers, buds, fruits, fruit skins, fruit kernels, aerial parts, whole plants, and mixtures thereof, and the like. Are leaves, stems, flowers or buds.
ヨクイニン（生薬名）は、ハトムギ（学名：Coix lachrymal-jobi L.）の種子部である。ハトムギは、中国、インドシナ地方原産の植物であって、日本では西南部の暖地で栽培されているイネ科ジュズダマ属に属する一年草であり、これらの地域から容易に入手することができる。ヨクイニンは、従来、利水滲湿、清熱、排膿、除痺、健脾止痛等の用途に用いられている。 Yokuinin (crude drug name) is the seed part of pearl barley (scientific name: Coix lachrymal-jobi L.). Coix, which is a plant native to the Indochinese region of China, is an annual plant belonging to the genus Juzudama, which is cultivated in the warm regions of southwestern Japan in Japan, and can be easily obtained from these regions. Yokuinin has been conventionally used for applications such as hydration of water, clear heat, drainage, paralysis, and pain in splenic spleen.
上記植物からの抽出物は、抽出原料を乾燥した後、そのまま、または粗砕機を用いて粉砕し、抽出溶媒による抽出に供することにより得ることができる。乾燥は天日で行ってもよいし、通常使用される乾燥機を用いて行ってもよい。また、ヘキサン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用してもよい。脱脂等の前処理を行うことにより、極性溶媒による抽出処理を効率よく行うことができる。 The extract from the above-mentioned plant can be obtained by drying the extraction raw material and then subjecting it to extraction as it is or after crushing it using a coarse crusher. Drying may be performed in the sun or using a commonly used dryer. Further, it may be used as an extraction raw material after being subjected to a pretreatment such as degreasing with a non-polar solvent such as hexane. By performing the pretreatment such as degreasing, the extraction treatment with the polar solvent can be efficiently performed.
抽出溶媒としては、極性溶媒を使用することが好ましく、例えば、水、親水性有機溶媒等が挙げられ、これらを単独でまたは２種以上を組み合わせて、室温または溶媒の沸点以下の温度で使用することが好ましい。 As the extraction solvent, it is preferable to use a polar solvent, and examples thereof include water and hydrophilic organic solvents. These are used alone or in combination of two or more at room temperature or at a temperature not higher than the boiling point of the solvent. It is preferable.
抽出溶媒として使用し得る水としては、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等のほか、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、濾過、イオン交換、浸透圧調整、緩衝化等が含まれる。したがって、本実施形態において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。 Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral water, mineral water, hot spring water, spring water, fresh water, and the like, as well as those that have been subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering and the like. Therefore, the water that can be used as the extraction solvent in the present embodiment also includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline and the like.
抽出溶媒として使用し得る親水性有機溶媒としては、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数１〜５の低級脂肪族アルコール；アセトン、メチルエチルケトン等の低級脂肪族ケトン；１，３−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数２〜５の多価アルコール等が挙げられる。 Hydrophilic organic solvents that can be used as the extraction solvent include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene. Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycol, propylene glycol and glycerin.
２種以上の極性溶媒の混合液を抽出溶媒として使用する場合、その混合比は適宜調整することができる。例えば、水と低級脂肪族アルコールとの混合液を抽出溶媒として使用する場合には、水と低級脂肪族アルコールとの混合比が９：１〜１：９（容量比）であることが好ましく、７：３〜２：８（容量比）であることがさらに好ましい。また、水と低級脂肪族ケトンとの混合液を使用する場合には、水と低級脂肪族ケトンとの混合比が９：１〜２：８（容量比）であることが好ましく、水と多価アルコールとの混合液を使用する場合には、水と多価アルコールとの混合比が５：５〜１：９（容量比）であることが好ましい。 When a mixed solution of two or more polar solvents is used as the extraction solvent, the mixing ratio can be adjusted appropriately. For example, when a mixed liquid of water and lower aliphatic alcohol is used as an extraction solvent, the mixing ratio of water and lower aliphatic alcohol is preferably 9: 1 to 1: 9 (volume ratio), It is more preferably 7: 3 to 2: 8 (volume ratio). When a mixed liquid of water and lower aliphatic ketone is used, it is preferable that the mixing ratio of water and lower aliphatic ketone is 9: 1 to 2: 8 (volume ratio). When a mixed liquid with a polyhydric alcohol is used, the mixing ratio of water and polyhydric alcohol is preferably 5: 5 to 1: 9 (volume ratio).
抽出処理は、抽出原料に含まれる可溶性成分を抽出溶媒に溶出させ得る限り特に限定はされず、常法に従って行うことができる。例えば、抽出原料の５〜１５倍量（質量比）の抽出溶媒に、抽出原料を浸漬し、常温または還流加熱下で可溶性成分を抽出させた後、濾過して抽出残渣を除去することにより抽出液を得ることができる。得られた抽出液から溶媒を留去するとペースト状の濃縮物が得られ、この濃縮物をさらに乾燥すると乾燥物が得られる。 The extraction treatment is not particularly limited as long as the soluble component contained in the extraction raw material can be eluted in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in 5 to 15 times the amount (mass ratio) of the extraction raw material (mass ratio), the soluble component is extracted at room temperature or under heating under reflux, and then extraction is performed by removing the extraction residue. A liquid can be obtained. The solvent is distilled off from the obtained extract to obtain a paste-like concentrate, and this concentrate is further dried to obtain a dry product.
以上のようにして得られる甘草葉抽出物、トウキ抽出物、キンギンカ抽出物およびヨクイニン抽出物は、所定の組み合わせにより（さらに好ましくは、後述する真珠タンパク質加水分解物との組み合わせにより）、優れたしわ改善作用を有するため、しわ改善用組成物に用いることができる。 Licorice leaf extract, Touki extract, King Ginka extract and Yokuinin extract obtained as described above are excellent in wrinkles according to a predetermined combination (more preferably, in combination with a pearl protein hydrolyzate described later). Since it has an improving effect, it can be used in a composition for improving wrinkles.
〔真珠タンパク質加水分解物の製造〕
本実施形態において用いる真珠タンパク質加水分解物は、真珠層を有する貝の貝殻および／または真珠を脱灰処理に付し、これにより得られる真珠タンパク質（コンキオリン）を加水分解してなるものである。
[Production of pearl protein hydrolyzate]
The pearl protein hydrolyzate used in the present embodiment is obtained by subjecting a shell and / or pearl of a shell having a pearl layer to a decalcification treatment and hydrolyzing the pearl protein (conchiolin) thus obtained.
真珠層を有する貝としては、例えば、ウグイスガイ科に属するアコヤ貝（学名：Pinctada fucata）；イガイ科に属するイガイ（学名：Mytilus coruscum）、ムラサキイガイ（学名：Mytilus edulis）；イシガイ科に属するイケチョウガイ（学名：Hyriopsis schlegelii）、カラスガイ（学名：Cristaria plicata）等が挙げられ、これらのうちアコヤ貝を用いるのが好ましい。 Examples of pearl oysters include pearl pearl oysters belonging to the family Musiidae (scientific name: Pinctada fucata); mussels belonging to the mussel family (scientific name: Mytilus coruscum), mussel mussels (scientific name: Mytilus edulis); Scientific name: Hyriopsis schlegelii), mussel (scientific name: Cristaria plicata) and the like can be mentioned, and of these, it is preferable to use pearl oysters.
真珠層を有する貝の貝殻および／または真珠は、そのまま、または粉砕して脱灰処理に付せられる。貝殻および／または真珠の脱灰処理は、常法により行えばよく、例えば、貝殻および／または真珠に酸またはその水溶液を添加して攪拌する。
脱灰処理に使用し得る酸としては、貝殻および／または真珠に含まれる炭酸カルシウム等の無機成分を十分に溶出させ得るものであれば特に限定されるものではないが、例えば、塩酸、硫酸、リン酸、硝酸等の無機酸；シュウ酸、炭酸、クエン酸、リンゴ酸、マレイン酸、酒石酸、酢酸、ギ酸等の有機酸等が挙げられ、これらのうちの１種を単独で使用してもよいし、２種以上の混酸を使用してもよい。
酸またはその水溶液の添加量は、貝殻および／または真珠に含まれる炭酸カルシウム等の無機成分を十分に溶出させ得る量であればよく、使用する酸の種類等に応じて適宜設定すればよい。
The shell and / or pearl of the shell having a nacre can be subjected to decalcification as it is or after being crushed. Decalcification of shells and / or pearls may be performed by a conventional method. For example, an acid or an aqueous solution thereof is added to the shells and / or pearls and stirred.
The acid that can be used for the decalcification treatment is not particularly limited as long as it can sufficiently elute inorganic components such as calcium carbonate contained in shells and / or pearls, but for example, hydrochloric acid, sulfuric acid, Inorganic acids such as phosphoric acid and nitric acid; organic acids such as oxalic acid, carbonic acid, citric acid, malic acid, maleic acid, tartaric acid, acetic acid and formic acid, and the like. Even if one of these is used alone Good, or two or more kinds of mixed acids may be used.
The amount of the acid or the aqueous solution thereof added may be any amount as long as it can sufficiently elute the inorganic components such as calcium carbonate contained in the shell and / or pearl, and may be appropriately set depending on the type of the acid used and the like.
脱灰処理により得られた処理液を遠心分離、濾過、デカンテーション等の固液分離手段に付して不溶物を回収し、必要に応じて回収した不溶物に精製水を添加して再度遠心分離、濾過等の洗浄操作を繰り返し、不溶物を回収する。そして、得られる不溶物を、所望により粉砕機等を用いて微粉砕し、常法により乾燥して真珠タンパク質（コンキオリン）を得ることができる。 The insoluble matter is recovered by subjecting the treated solution obtained by deashing to solid-liquid separation means such as centrifugation, filtration, decantation, etc., and if necessary, adding purified water to the recovered insoluble matter and centrifuging again. Insoluble matter is recovered by repeating washing operations such as separation and filtration. Then, the obtained insoluble matter can be finely pulverized using a pulverizer or the like, if desired, and dried by a conventional method to obtain a pearl protein (conchiolin).
そして、得られた真珠タンパク質（コンキオリン）を酸またはアルカリの水溶液を用いて加水分解する。
真珠タンパク質（コンキオリン）の加水分解処理に使用し得る酸としては、例えば、塩酸、硫酸等が挙げられ、これらのうちの１種を単独で使用してもよいし、２種以上を混合して使用してもよい。
また、真珠タンパク質（コンキオリン）の加水分解処理に使用し得るアルカリとしては、例えば、水酸化ナトリウム、水酸化カリウム等が挙げられ、これらのうちの１種を単独で使用してもよいし、２種以上を混合して使用してもよい。
Then, the obtained pearl protein (conchiolin) is hydrolyzed using an aqueous solution of acid or alkali.
Examples of the acid that can be used for the hydrolysis treatment of pearl protein (conchiolin) include hydrochloric acid and sulfuric acid, and one of these may be used alone, or two or more of them may be mixed and used. May be used.
In addition, examples of the alkali that can be used for the hydrolysis treatment of pearl protein (conchiolin) include sodium hydroxide and potassium hydroxide, and one of these may be used alone, or 2 You may use it in mixture of 2 or more types.
酸またはアルカリの水溶液を使用して加水分解する場合、酸またはアルカリの水溶液の添加量や当該水溶液における酸またはアルカリの濃度は、貝殻および／または真珠に含まれる真珠タンパク質（コンキオリン）を加水分解し得るが、完全にアミノ酸にまで分解し得ない量であればよく、使用する酸またはアルカリの種類等に応じて当該水溶液の添加量や当該水溶液における酸またはアルカリの濃度を適宜変更することができる。
また、加水分解処理は、０〜１３０℃、好ましくは５０〜１１０℃の温度条件の下、３０分〜１０日間程度、好ましくは５時間〜５日間程度行うことができる。
When hydrolysis is performed using an acid or alkali aqueous solution, the addition amount of the acid or alkali aqueous solution or the concentration of the acid or alkali in the aqueous solution causes hydrolysis of the pearl protein (conchiolin) contained in the shell and / or pearl. However, the amount may be such that it cannot be completely decomposed into amino acids, and the addition amount of the aqueous solution or the concentration of the acid or alkali in the aqueous solution may be appropriately changed depending on the type of the acid or alkali used. .
Further, the hydrolysis treatment can be performed under a temperature condition of 0 to 130 ° C., preferably 50 to 110 ° C., for about 30 minutes to 10 days, preferably about 5 hours to 5 days.
このようにして加水分解処理により得られた溶液から酸またはアルカリを除去し、必要に応じて限外濾過処理に付して高分子ペプタイドを除去し、さらに濃縮、乾燥等の処理に付することで、真珠タンパク質加水分解物を得ることができる。
酸またはアルカリは、加水分解処理により得られた溶液から常法により除去することができ、例えば、凍結乾燥、溶液中の酸またはアルカリを中和して脱塩する方法等が挙げられる。
In this way, the acid or alkali is removed from the solution obtained by the hydrolysis treatment, and if necessary, subjected to ultrafiltration treatment to remove the polymer peptide, and further subjected to treatments such as concentration and drying. Thus, a pearl protein hydrolyzate can be obtained.
The acid or alkali can be removed from the solution obtained by the hydrolysis treatment by a conventional method, and examples thereof include lyophilization and a method of neutralizing the acid or alkali in the solution to desalt.
以上のようにして得られる真珠タンパク質加水分解物は、甘草葉抽出物との組み合わせにより（さらに好ましくは、トウキ抽出物、キンギンカ抽出物およびヨクイニン抽出物との組み合わせにより）、優れたしわ改善作用を有するため、しわ改善用組成物に用いることができる。 The pearl protein hydrolyzate obtained as described above has an excellent wrinkle-improving effect by a combination with a licorice leaf extract (more preferably, by a combination with a Touki extract, a Goldfish extract and a Yokuinin extract). Since it has, it can be used for a composition for improving wrinkles.
〔しわ改善用組成物〕
本実施形態に係るしわ改善用組成物は、甘草葉抽出物と、トウキ抽出物、キンギンカ抽出物、ヨクイニン抽出物および真珠タンパク質加水分解物の４種のうち少なくとも１種とを組み合わせてなるものである（以下、「天然物由来成分の混合物」ということがある）。
本実施形態のしわ改善用組成物は、医薬品、医薬部外品、化粧品等の幅広い用途に使用することができる。
[Composition for improving wrinkles]
The wrinkle-improving composition according to the present embodiment comprises a combination of a licorice leaf extract and at least one selected from four species of a Japanese laurel extract, a Kingfish extract, a Yokuinin extract, and a pearl protein hydrolyzate. (Hereinafter, it may be referred to as a “mixture of components derived from natural products”).
The wrinkle-improving composition of the present embodiment can be used for a wide range of applications such as pharmaceuticals, quasi drugs, and cosmetics.
しわは、皮膚の柔軟性や弾力性の低下が要因となって形成されるが、皮膚の柔軟性や弾力性の低下は、細胞外マトリックスの主要構成成分であるコラーゲンやエラスチン等の産生量の減少、これらの分解や変質が重要な要因となっている。なかでも、真皮の主要構成物質であるＩ型コラーゲンの減少は、皮膚の柔軟性や弾力性の低下、ひいてはしわの形成と密接に関わっている。
これに対し、本実施形態に係るしわ改善用組成物は、甘草葉抽出物を必須成分としている。甘草葉抽出物は、皮膚線維芽細胞に対し優れたＩ型コラーゲン産生促進作用を有しており、さらに皮膚線維芽細胞の増殖促進作用、保湿・バリア機能向上作用、抗酸化作用をも有している。本実施形態においては、かかる甘草葉抽出物のＩ型コラーゲン産生促進作用等が、しわ改善効果に寄与しているものと認められる。
そして、本実施形態においては、トウキ抽出物、キンギンカ抽出物、ヨクイニン抽出物および真珠タンパク質加水分解物の４種のうち少なくとも１種を、甘草葉抽出物と組み合わせることにより、甘草葉抽出物の有効性が顕著に向上し、しわ改善効果に特に優れた組成物とすることができる。
Wrinkles are formed due to a decrease in the flexibility and elasticity of the skin, but a decrease in the flexibility and elasticity of the skin is due to the production of collagen, elastin, etc., which are the major constituents of the extracellular matrix. Decrease and their decomposition and alteration are important factors. In particular, the reduction of type I collagen, which is a major constituent of the dermis, is closely related to the reduction of the flexibility and elasticity of the skin and the formation of wrinkles.
On the other hand, the wrinkle-improving composition according to the present embodiment uses the licorice leaf extract as an essential component. Licorice leaf extract has an excellent type I collagen production-promoting effect on skin fibroblasts, and also has a skin fibroblast proliferation-promoting effect, moisturizing / barrier function improving effect, and antioxidant effect. ing. In the present embodiment, it is recognized that the type I collagen production promoting action of the licorice leaf extract contributes to the wrinkle improving effect.
Then, in the present embodiment, by combining at least one of the four types of Touki extract, Kingfish extract, Yokuinin extract and pearl protein hydrolyzate with the licorice leaf extract, the licorice leaf extract is effective. It is possible to obtain a composition in which the property is remarkably improved and the wrinkle improving effect is particularly excellent.
トウキ抽出物は、クローディン−１やインボルクリン等の基底膜成分の産生を促進する作用を有しており、さらに皮膚線維芽細胞の増殖促進作用、保湿・バリア機能向上作用、タンパク質抗糖化作用をも有している。
ここで、基底膜は、表皮と真皮との境界部に存在し両者を繋ぎ止めるだけでなく、皮膚機能の維持に重要な役割を果たしている。基底膜成分の減少や基底膜の構造変化が起こると、皮膚の保湿機能や弾力性が低下し、しわ形成の一因となる。
本実施形態においては、甘草葉抽出物により産生促進されたＩ型コラーゲンにより真皮の機能が改善されるとともに、トウキ抽出物により産生促進された基底膜成分により基底膜の機能が改善され、皮膚の柔軟性や弾力性が向上することで、しわ改善効果が相乗的に発揮されるものと考えられる。
トウキ抽出物を甘草葉抽出物と組み合わせる場合、しわ改善効果を相乗的に発揮させやすくする観点から、甘草葉抽出物１００質量部に対するトウキ抽出物の質量割合は、下限値が３０質量部以上であることが好ましく、４０質量部以上であることが特に好ましい。また、上記トウキ抽出物の質量割合は、上限値が７０質量部以下であることが好ましく、６０質量部以下であることが特に好ましい。
なお、本明細書において、天然物由来成分の質量割合はいずれも固形分換算である。
Touki extract has the action of promoting the production of basement membrane components such as claudin-1 and involucrin, and further has the action of promoting the growth of skin fibroblasts, the action of improving moisturizing / barrier function, and the action of protein anti-glycation. I also have.
Here, the basement membrane is present at the boundary between the epidermis and the dermis and plays an important role not only for connecting the two but also for maintaining the skin function. When the amount of basement membrane components is reduced or the structure of basement membrane is changed, the moisturizing function and elasticity of the skin are reduced, which contributes to the formation of wrinkles.
In the present embodiment, the type I collagen production-promoted by the licorice leaf extract improves the function of the dermis, and the basement membrane component production-promoted by the Touki extract improves the function of the basement membrane. It is considered that wrinkle improvement effect is synergistically exerted by improving flexibility and elasticity.
When the Touki extract is combined with the licorice leaf extract, the mass ratio of the Toki extract to 100 parts by mass of the licorice leaf extract has a lower limit value of 30 parts by mass or more, from the viewpoint of facilitating synergistic wrinkle improving effect. It is preferably present, and particularly preferably 40 parts by mass or more. Further, the upper limit of the mass ratio of the Touki extract is preferably 70 parts by mass or less, and particularly preferably 60 parts by mass or less.
In addition, in this specification, the mass ratios of the components derived from natural products are in terms of solid content.
キンギンカ抽出物は、抗酸化作用を有しており、さらにタンパク質抗糖化作用をも有している。このため、キンギンカ抽出物を甘草葉抽出物と組み合わせると、甘草葉抽出物により産生促進されたＩ型コラーゲンは、酸化や糖化による変性を受けにくくなり、しわ改善効果がより顕著に発揮されるものと認められる。
キンギンカ抽出物を甘草葉抽出物と組み合わせる場合、しわ改善効果をより顕著に発揮させる観点から、甘草葉抽出物１００質量部に対するキンギンカ抽出物の質量割合は、下限値が５質量部以上であることが好ましく、１０質量部以上であることが特に好ましい。また、上記キンギンカ抽出物の質量割合は、上限値が３０質量部以下であることが好ましく、２０質量部以下であることが特に好ましい。
Goldfish extract has an antioxidant effect and also has a protein anti-glycation effect. For this reason, when King Ginkgo extract is combined with a licorice leaf extract, type I collagen production-promoted by the licorice leaf extract is less susceptible to denaturation due to oxidation or saccharification, and a wrinkle improving effect is more significantly exhibited. Is recognized.
When combining a goldfish extract with a licorice leaf extract, the lower limit of the mass ratio of the goldfish extract to 100 parts by weight of the licorice leaf extract is 5 parts by mass or more, from the viewpoint of more significantly exhibiting a wrinkle improving effect. Is preferred, and particularly preferably 10 parts by mass or more. In addition, the upper limit of the mass ratio of the King Ginkgo extract is preferably 30 parts by mass or less, and particularly preferably 20 parts by mass or less.
ヨクイニン抽出物は、皮膚に対する保湿作用やバリア機能向上作用を有しており、さらにエラスチン産生促進作用も有している。そのため、ヨクイニン抽出物は、皮膚の柔軟性を回復し、また皮膚の恒常性の維持に寄与すると認められる。そして、これらの作用を有するヨクイニン抽出物を甘草葉抽出物と組み合わせることで、甘草葉抽出物によるＩ型コラーゲン産生促進作用などと相乗的に寄与し、しわ改善作用がより顕著に発揮されるものと考えられる。
ヨクイニン抽出物を甘草葉抽出物と組み合わせる場合、しわ改善効果を相乗的に発揮させやすくする観点から、甘草葉抽出物１００質量部に対するヨクイニン抽出物の質量割合は、下限値が０．５質量部以上であることが好ましく、２質量部以上であることが特に好ましい。また、上記ヨクイニン抽出物の質量割合は、上限値が１０質量部以下であることが好ましく、５質量部以下であることが特に好ましい。
Yokuinin extract has a moisturizing action on the skin and a barrier function improving action, and further has an elastin production promoting action. Therefore, it is recognized that Yokuinin extract restores skin flexibility and contributes to the maintenance of skin homeostasis. And, by combining Yokuinin extract having these actions with licorice leaf extract, it contributes synergistically with the type I collagen production promoting action by the licorice leaf extract, and the wrinkle improving action is more significantly exhibited. it is conceivable that.
When the Yokuinin extract is combined with the licorice leaf extract, the lower limit of the mass ratio of the Yokuinin extract to 100 parts by mass of the licorice leaf extract is 0.5 parts by mass, from the viewpoint of facilitating synergistic wrinkle improving effect. It is preferably at least above, and particularly preferably at least 2 parts by mass. Further, the upper limit of the mass ratio of the above-mentioned Yokuinin extract is preferably 10 parts by mass or less, and particularly preferably 5 parts by mass or less.
真珠タンパク質加水分解物は、抗酸化作用、保湿作用、タンパク質抗糖化作用、皮膚線維芽細胞増殖促進作用等を有しているほか、特に優れたエラスチン産生促進作用を有している。このため、甘草葉抽出物により産生促進されたＩ型コラーゲンと、真珠タンパク質加水分解物により産生促進されたエラスチンとにより、皮膚（特に真皮）における細胞外マトリックスの構成が回復し、皮膚の柔軟性や弾力性が向上することで、しわ改善効果がより顕著に発揮されるものと考えられる。
真珠タンパク質加水分解物を甘草葉抽出物と組み合わせる場合、しわ改善効果をより顕著に発揮させる観点から、甘草葉抽出物１００質量部に対する真珠タンパク質加水分解物の質量割合は、下限値が３質量部以上であることが好ましく、８質量部以上であることが特に好ましい。また、上記真珠タンパク質加水分解物の質量割合は、上限値が３０質量部以下であることが好ましく、１８質量部以下であることが特に好ましい。
The pearl protein hydrolyzate has an antioxidant action, a moisturizing action, a protein anti-glycation action, a skin fibroblast proliferation promoting action, and the like, and also a particularly excellent elastin production promoting action. Therefore, the type I collagen production-promoted by the licorice leaf extract and the elastin production-promoted by the pearl protein hydrolyzate restore the composition of the extracellular matrix in the skin (particularly the dermis), and the flexibility of the skin. It is considered that the wrinkle improving effect is more remarkably exhibited by improving the elasticity and elasticity.
When the pearl protein hydrolyzate is combined with the licorice leaf extract, the lower limit of the mass ratio of the pearl protein hydrolyzate to 100 parts by mass of the licorice leaf extract is 3 parts by mass, from the viewpoint of more significantly exhibiting a wrinkle improving effect. The amount is preferably the above, and more preferably 8 parts by mass or more. The upper limit of the mass ratio of the pearl protein hydrolyzate is preferably 30 parts by mass or less, and particularly preferably 18 parts by mass or less.
甘草葉抽出物と組み合わせる、トウキ抽出物、キンギンカ抽出物、ヨクイニン抽出物および真珠タンパク質加水分解物の４種は、少なくとも１種を甘草葉抽出物と組み合わせればよいが、しわ改善効果をより顕著に発揮させる観点から、２種以上を甘草葉抽出物と組み合わせることが好ましく、４種全てを組み合わせることが特に好ましい。 At least one of four types of Touki extract, King Ginkgo extract, Yokuinin extract and pearl protein hydrolyzate, which are combined with the licorice leaf extract, may be combined with the licorice leaf extract, but the wrinkle improving effect is more remarkable. From the viewpoint of exhibiting the above, it is preferable to combine two or more kinds with the licorice leaf extract, and it is particularly preferable to combine all four kinds.
本実施形態のしわ改善用組成物は、上記天然物由来成分の組み合わせのみからなるものでもよいし、当該組み合わせを製剤化したものでもよい。製剤化する場合は、デキストリン、シクロデキストリン等の薬学的に許容し得るキャリアーその他任意の助剤を用いて、常法に従い、粉末状、顆粒状、錠剤状、液状等の任意の剤形に製剤化することができる。この際、助剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯味・矯臭剤等を用いることができる。しわ改善用組成物は、他の組成物（例えば、後述する皮膚化粧料等）に配合して使用することができるほか、軟膏剤、外用液剤、貼付剤等として使用することができる。 The wrinkle-improving composition of the present embodiment may be a combination of the above-mentioned natural product-derived components alone, or may be a formulation of the combination. In the case of formulation, a pharmaceutically acceptable carrier such as dextrin or cyclodextrin and any other auxiliaries are used and prepared into any dosage form such as powder, granules, tablets and liquid according to a conventional method. Can be converted. At this time, as the auxiliary agent, for example, an excipient, a binder, a disintegrating agent, a lubricant, a stabilizer, a flavoring agent, a flavoring agent and the like can be used. The composition for improving wrinkles can be used by being mixed with other compositions (for example, skin cosmetics described later), and can also be used as an ointment, an external preparation, a patch and the like.
本実施形態のしわ改善用組成物を製剤化した場合、当該しわ改善用組成物における、上記天然物由来成分の混合物の合計含有量は、特に限定されるものではなく、目的に応じて適宜設定することができる。 When the wrinkle-improving composition of the present embodiment is formulated, the total content of the mixture of the natural product-derived components in the wrinkle-improving composition is not particularly limited and is appropriately set according to the purpose. can do.
なお、本実施形態のしわ改善用組成物は、必要に応じて、しわ改善作用を有する他の天然抽出物等を、上記天然物由来成分の混合物とともに配合して有効成分として用いることができる。 The wrinkle-improving composition of the present embodiment can be used as an active ingredient, if necessary, by blending another natural extract or the like having a wrinkle-improving action together with the above-mentioned mixture of natural product-derived ingredients.
本実施形態のしわ改善用組成物の患者に対する投与方法としては、経皮投与、経口投与等が挙げられ、疾患の種類に応じて、その予防・治療等に好適な方法を適宜選択することができるが、経皮投与であることが好ましい。
また、本実施形態のしわ改善用組成物の投与量は、疾患の種類、重症度、患者の個人差、投与方法、投与期間等によって適宜増減すればよい。
Examples of the method for administering the wrinkle-improving composition of the present embodiment to a patient include transdermal administration and oral administration. Depending on the type of disease, a suitable method for prevention / treatment thereof can be appropriately selected. Yes, but transdermal administration is preferred.
Further, the dose of the wrinkle-improving composition of the present embodiment may be appropriately increased or decreased depending on the type of disease, severity, individual difference of patient, administration method, administration period and the like.
本実施形態のしわ改善用組成物は、上記天然物由来成分の混合物により相乗的に発揮されるしわ改善作用を通じて、皮膚のしわを改善するとともに、しわの形成を抑制することができ、これにより、しわの形成に基づく皮膚の老化症状を改善することができ、また、しわの形成に基づく皮膚の老化症状を予防または治療することができる。 The wrinkle-improving composition of the present embodiment improves wrinkles of the skin through the wrinkle-improving action synergistically exhibited by the mixture of the natural product-derived components, and can suppress the formation of wrinkles, which results in The aging symptoms of the skin due to the formation of wrinkles can be improved, and the aging symptoms of the skin due to the formation of wrinkles can be prevented or treated.
本実施形態のしわ改善用組成物によるしわ改善効果は、例えば、「新規効能取得のための抗シワ製品評価ガイドライン」（前述した非特許文献１）や“Guidelines for Evaluation of Anti-wrinkle products”（前述した非特許文献２）（以下、これらを総称して単に「ガイドライン」と称することがある）に準拠した方法により、評価することができる。
より具体的には、本実施形態に係るしわ改善用組成物は、そのしわ改善作用により、しわを小さく、目立たなくすることができ、かかる効果は、例えば、上記ガイドラインに準拠したしわの三次元解析法において、しわ平均深さ、最大しわ平均深さ、最大しわ最大深さ、総しわ体積といったパラメータを減少させる効果として確認することができる。
また、本実施形態に係るしわ改善組成物は、そのしわ改善作用により、肌の表面をなめらかにすることができ、かかる効果は、例えば、上記ガイドラインに準拠したしわの三次元解析法において、Ｒａ値（粗さ曲線の算術平均粗さ）、Ｒｙ値（粗さ曲線の最大高さ）といったパラメータを減少させる効果として確認することができる。
本実施形態においては、上記パラメータの中でも、最大しわ平均深さ、総しわ体積、およびＲｙ値（粗さ曲線の最大高さ）の少なくとも１種以上の減少効果を確認できることが特に好ましい。
The wrinkle-reducing effect of the wrinkle-improving composition of the present embodiment is, for example, “Guideline for Evaluation of Anti-Wrinkle Products for Obtaining New Efficacy” (Non-patent Document 1 described above) and “Guidelines for Evaluation of Anti-wrinkle products” ( The evaluation can be performed by a method based on the aforementioned non-patent document 2) (hereinafter, these may be collectively referred to simply as “guidelines”).
More specifically, the wrinkle-improving composition according to the present embodiment, by its wrinkle-improving action, can reduce wrinkles to be small and inconspicuous, and such effects are, for example, three-dimensional wrinkle conforming to the above guidelines. In the analysis method, it can be confirmed as an effect of reducing parameters such as wrinkle average depth, maximum wrinkle average depth, maximum wrinkle maximum depth, and total wrinkle volume.
In addition, the wrinkle-improving composition according to the present embodiment can smooth the surface of the skin due to its wrinkle-improving action, and such an effect can be obtained, for example, in the three-dimensional analysis method of wrinkles in accordance with the above guidelines. It can be confirmed as an effect of reducing parameters such as a value (arithmetic mean roughness of roughness curve) and a Ry value (maximum height of roughness curve).
In the present embodiment, among the above parameters, it is particularly preferable to be able to confirm the effect of reducing at least one of the maximum wrinkle average depth, the total wrinkle volume, and the Ry value (maximum height of roughness curve).
本実施形態のしわ改善用組成物は、優れたしわ改善作用を有するため、例えば、皮膚外用剤に配合するのに好適である。この場合に、配合するしわ改善用組成物は、上記天然物由来成分の混合物をそのまま配合してもよいし、上記天然物由来成分の混合物から製剤化したものを配合してもよい。 The wrinkle-improving composition of the present embodiment has an excellent wrinkle-improving action, and thus is suitable for incorporation into, for example, a skin external preparation. In this case, the wrinkle-improving composition to be blended may be a mixture of the natural product-derived components as it is, or may be a formulation prepared from the mixture of the natural product-derived components.
ここで、皮膚外用剤としては、その区分に制限はなく、後述する皮膚化粧料のほか、経皮的に使用される医薬部外品、医薬品等を幅広く含むものである。 Here, the external preparation for skin is not limited in its classification, and includes a wide variety of quasi-drugs, pharmaceuticals and the like, which are used transdermally, in addition to the skin cosmetics described below.
本実施形態のしわ改善用組成物は、優れたしわ改善作用を有するので、これらの作用機構に関する研究のための試薬としても好適に利用することができる。 Since the wrinkle-improving composition of the present embodiment has an excellent wrinkle-improving action, it can be suitably used as a reagent for research on these action mechanisms.
〔しわ改善用皮膚化粧料〕
上記実施形態に係るしわ改善用組成物は、上記天然物由来成分の混合物の作用に基づく優れたしわ改善作用を発揮するため、皮膚化粧料に配合するのに好適である。この場合、配合するしわ改善用組成物は、上記天然物由来成分の混合物をそのまま配合してもよいし、上記天然物由来成分の混合物から製剤化したものを配合してもよい。上記しわ改善用組成物を配合することにより、皮膚化粧料をしわ改善用途に好適に用いることができる。
[Wrinkle-improving skin cosmetics]
The wrinkle-improving composition according to the above embodiment exerts an excellent wrinkle-improving action based on the action of the mixture of the natural product-derived components, and thus is suitable for incorporation into a skin cosmetic. In this case, the wrinkle-improving composition to be blended may be a mixture of the above natural product-derived components as it is, or may be a formulation prepared from the above mixture of natural product-derived components. By blending the composition for improving wrinkles, the skin cosmetic can be preferably used for the purpose of improving wrinkles.
上記実施形態のしわ改善用組成物を配合し得る皮膚化粧料の種類は特に限定されるものではなく、例えば、軟膏、クリーム、乳液、化粧水、ローション、ジェル、美容オイル、パック、ファンデーション等が挙げられる。 The type of skin cosmetics that can be blended with the wrinkle improving composition of the above embodiment is not particularly limited, and examples thereof include ointments, creams, emulsions, lotions, lotions, gels, beauty oils, packs, foundations and the like. Can be mentioned.
上記しわ改善用組成物を皮膚化粧料に配合する場合、その配合量は、皮膚化粧料の種類に応じて適宜調整することができる。より好適には、上記天然物由来成分の混合物の固形分に換算した上記しわ改善用組成物の配合量は、下限値が約０．０００１質量％以上であることが好ましく、約０．００１質量％以上であることがさらに好ましく、約０．００４質量％以上であることが特に好ましい。また、上記天然物由来成分の混合物に換算した上記しわ改善用組成物の配合量は、上限値が約１０質量％以下であることが好ましく、約１質量％以下であることがさらに好ましく、約０．１質量％以下であることが特に好ましい。 When the above-mentioned composition for improving wrinkles is added to a skin cosmetic, the amount thereof can be appropriately adjusted depending on the type of skin cosmetic. More preferably, the lower limit of the amount of the composition for improving wrinkles converted to the solid content of the mixture of components derived from the natural product is preferably about 0.0001% by mass or more, and about 0.001% by mass. % Or more, and particularly preferably about 0.004% by mass or more. The upper limit of the amount of the wrinkle-improving composition converted to the mixture of the natural product-derived components is preferably about 10% by mass or less, more preferably about 1% by mass or less, It is particularly preferably 0.1% by mass or less.
上記皮膚化粧料は、上記天然物由来成分の混合物が有するしわ改善作用を妨げない限り、通常の皮膚化粧料の製造に用いられる主剤、助剤またはその他の成分、例えば、収斂剤、殺菌・抗菌剤、美白剤、紫外線吸収剤、保湿剤、細胞賦活剤、消炎・抗アレルギー剤、抗酸化・活性酸素除去剤、油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、香料等を併用することができる。このように併用することで、より一般性のある製品となり、また、併用された他の有効成分との間の相乗作用が通常期待される以上の優れた効果をもたらすことがある。 The skin cosmetic is a main ingredient, auxiliary agent or other ingredient used in the production of ordinary skin cosmetics, for example, astringent, bactericidal / antibacterial, as long as it does not interfere with the wrinkle improving action of the mixture of natural product-derived ingredients. Agents, whitening agents, UV absorbers, moisturizers, cell activators, anti-inflammatory / anti-allergic agents, antioxidants / active oxygen scavengers, oils, waxes, hydrocarbons, fatty acids, alcohols, esters, interfaces An activator, a fragrance, etc. can be used together. Such combined use results in a more general product, and synergistic action with other active ingredients used in combination may bring about an excellent effect more than normally expected.
本実施形態のしわ改善用皮膚化粧料は、上記天然物由来成分の混合物により相乗的に発揮されるしわ改善作用を通じて、皮膚のしわを改善するとともに、しわの形成を抑制することができ、これにより、しわの形成に基づく皮膚の老化症状を改善することができ、また、しわの形成に基づく皮膚の老化症状を予防または治療することができる。 The wrinkle-improving skin cosmetic composition of the present embodiment is capable of improving wrinkles on the skin and suppressing the formation of wrinkles through the wrinkle-improving action synergistically exhibited by the mixture of the natural product-derived components. Thereby, the skin aging symptoms due to wrinkle formation can be improved, and the skin aging symptoms due to wrinkle formation can be prevented or treated.
以上説明した実施形態は、本発明の理解を容易にするために記載されたものであって、本発明を限定するために記載されたものではない。したがって、上記実施形態に開示された各要素は、本発明の技術的範囲に属する全ての設計変更や均等物をも含む趣旨である。 The embodiments described above are described to facilitate the understanding of the present invention, and are not described to limit the present invention. Therefore, each element disclosed in the above embodiments is intended to include all design changes and equivalents within the technical scope of the present invention.
以下、配合例、試験例等を示し、本発明を具体的に説明するが、本発明は下記の各例に何ら制限されるものではない。 Hereinafter, the present invention will be specifically described with reference to formulation examples, test examples and the like, but the present invention is not limited to the following examples.
〔製造例１〕しわ改善用組成物の製造
下記に示す成分を常法により混合し、しわ改善用組成物を調製した。
なお、用いた５種の天然物由来成分は、いずれも丸善製薬社製である。また、これらの配合量は固形分換算値であり、固形分換算値は、医薬部外品原料規格２００６の一般試験法に収載された蒸発残分試験法に準じて測定した。
[Production Example 1] Production of wrinkle improving composition The following components were mixed by a conventional method to prepare a wrinkle improving composition.
The five kinds of natural product-derived components used are manufactured by Maruzen Pharmaceutical Co., Ltd. In addition, these blending amounts are solid content conversion values, and the solid content conversion values were measured according to the evaporation residue test method listed in the general test method of Quasi-drug Raw Material Standard 2006.
〔配合例１〕
下記組成に従い、化粧水を常法により製造した。
しわ改善用組成物（製造例１） ２．００質量％
（天然物由来成分５種の合計量 ０．０１２０質量％）
クエン酸 ０．０４質量％
クエン酸ナトリウム ０．１６質量％
エデト酸二ナトリウム ０．０３質量％
メチルパラベン ０．１５質量％
ＰＰＧ−１３デシルテトラデセス−２４ ０．１０質量％
フェノキシエタノール ０．３０質量％
キサンタンガム ０．５０質量％
精製水 残部（全量を１００質量％とする）
[Formulation Example 1]
A lotion was prepared by a conventional method according to the following composition.
Wrinkle improving composition (Production Example 1) 2.00% by mass
(Total amount of 5 kinds of natural product-derived components 0.0120% by mass)
Citric acid 0.04 mass%
Sodium citrate 0.16% by mass
Disodium edetate 0.03% by mass
Methyl paraben 0.15 mass%
PPG-13 decyl tetradeceth-24 0.10 mass%
Phenoxyethanol 0.30% by mass
Xanthan gum 0.50% by mass
Purified water balance (total amount is 100% by mass)
〔比較配合例１〕
製造例１のしわ改善用組成物に代えて、５０質量％ １，３−ブチレングリコールを配合した以外は、配合例１と同様にして化粧水を製造した。
[Comparative formulation example 1]
A lotion was produced in the same manner as in Preparation Example 1 except that 50% by mass of 1,3-butylene glycol was added instead of the composition for improving wrinkles of Preparation Example 1.
〔試験例〕しわ改善作用試験
上記のようにして得られた配合例１および比較配合例１の化粧水を用い、上記ガイドライン（非特許文献１および２）に準拠して、以下のようにしわ改善作用を試験した。
[Test example] Wrinkle improving action test Using the lotions of the formulation example 1 and the comparative formulation example 1 obtained as described above, in accordance with the above guidelines (Non-patent documents 1 and 2), The improving effect was tested.
左右の目尻に同程度のしわを有する女性２３名（平均：５０．００歳，標準偏差：１．８６歳）を被験者として選抜した。なお、評価部位の皮膚に、試験の結果に影響を及ぼす可能性のある因子（皮膚炎症，湿疹，外傷等）がある者；評価部位に影響を与えるような美容医療（ボトックス注射，ヒアルロン酸やコラーゲンの注入，フォトフェイシャルなど）を受けた経験のある者；などは、被験者から除外した。 Twenty-three women (average: 50.00 years old, standard deviation: 1.86 years old) having similar wrinkles on the left and right corners of the eyes were selected as subjects. Those who have factors (skin inflammation, eczema, trauma, etc.) that may affect the test results on the skin at the evaluation site; cosmetic medicine (botox injection, hyaluronic acid, etc.) that affects the evaluation site. Those who have undergone collagen injection, photofacial, etc.) were excluded from the subjects.
各被験者には、左右の目尻の片側に配合例１の化粧水を、もう片側に比較配合例１の化粧水を、それぞれ朝晩の１日２回、洗顔後に、１回あたり約２滴ずつ、４週間にわたって塗布させた。各被験者において両化粧水を左右のどちらに塗布させるかは、無作為に割り付けた。
試験開始日、および試験開始４週後に、目尻に存在するシワを評価した。評価にあたっては、洗顔後、環境試験室（室温２０〜２４℃，湿度４５〜５５％）で１５分間以上馴化させた後、両側の目尻の対象部位について、専門家の目視評価を行うとともに、目尻に存在するシワを直接三次元測定した。
For each test subject, the lotion of Formulation Example 1 was applied to one side of the left and right outer corners of the eye, and the lotion of Comparative Formulation Example 1 was applied to the other side, twice a day in the morning and evening, and after washing the face, about 2 drops each time, It was applied for 4 weeks. It was randomly assigned to each subject whether to apply both lotions to the left or right.
The wrinkles present in the outer corners of the eyes were evaluated on the test start day and four weeks after the test started. In the evaluation, after washing the face, after acclimatizing for 15 minutes or more in an environmental test room (room temperature 20 to 24 ° C, humidity 45 to 55%), a visual evaluation by an expert is performed on the target parts of the outer corners of the eyes, and the outer corners of the eyes are also evaluated. The wrinkles present in 3D were directly measured in three dimensions.
目視評価においては、２名の専門家がそれぞれ目尻のしわを目視観察し、上記ガイドラインのしわグレード標準写真（グレード０〜７）に基づき、しわの状態をスコア付けした。なお、しわの状態が各グレードの標準写真に当て嵌まらない場合には、中間値および１／４値のスコアにて評価した。 In the visual evaluation, two experts visually observed the wrinkles on the outer corners of the eyes, and scored the wrinkle state based on the wrinkle grade standard photographs (grades 0 to 7) of the above guidelines. When the wrinkle state did not apply to the standard photographs of each grade, evaluation was made using the intermediate value and quarter score.
三次元解析においては、両側の目尻の対象部位について、皮膚用光学三次元測定システム（PRIMOS，GFメステクニク社製）を用いて測定し、三次元データを取得した。得られた三次元データを用い、PRIMOS付属の解析ソフトウェアにより、試験開始日および試験開始４週後の三次元データで解析範囲の位置を合わせて解析した。
しわの解析は、しわ平均深さ、最大しわ平均深さ、最大しわ最大深さ、総しわ体積、Ra値（粗さ曲線の算術平均粗さ）、およびRy値（粗さ曲線の最大高さ）の６項目のパラメータにて評価した。
In the three-dimensional analysis, the three-dimensional data were obtained by measuring the target parts of the outer corners of the eyes using an optical three-dimensional measurement system for skin (PRIMOS, manufactured by GF Mesteknik). Using the obtained three-dimensional data, the analysis software attached to PRIMOS was used to analyze the position of the analysis range with the three-dimensional data on the test start date and four weeks after the test start.
Wrinkle analysis includes wrinkle average depth, maximum wrinkle average depth, maximum wrinkle maximum depth, total wrinkle volume, Ra value (arithmetic mean roughness of roughness curve), and Ry value (maximum height of roughness curve). ) Was evaluated by the parameters of 6 items.
得られた結果について、シャピロ−ウィルク検定および尖度・歪度により正規性を検定し、パラメトリック検定には対応のあるｔ検定を行い、ノンパラメトリック検定にはウィルコクソン符号順位検定およびボンフェローニ補正を行った。配合例１と比較配合例１との比較は、開始日から開始４週後の変化量を用いてＲＭ ＡＮＯＶＡを行った。なお、目視評価においては、２名の専門家による評価の間で級内相関係数が０．８を超えているものについて解析した。
それぞれの検定においては、ｐ＜０．０５を有意差とした。また、開始日からの変化率は、下記式により算出した。
開始日からの変化率（％）＝（４週後の値−開始日の値）／開始日の値×１００
結果を表２および表３に示す。
Regarding the obtained results, normality is tested by Shapiro-Wilk test and kurtosis / skewness, corresponding t test is performed for parametric test, and Wilcoxon signed rank test and Bonferroni correction are performed for nonparametric test. It was For the comparison between the formulation example 1 and the comparative formulation example 1, RM ANOVA was performed using the amount of change 4 weeks after the start from the start date. In addition, in the visual evaluation, analysis was performed for those having an intraclass correlation coefficient of more than 0.8 between the evaluations by two experts.
In each test, p <0.05 was regarded as a significant difference. The rate of change from the start date was calculated by the following formula.
Rate of change from start date (%) = (value after 4 weeks-value on start date) / value on start date x 100
The results are shown in Tables 2 and 3.
表２に示すように、専門家の目視判定によるしわグレード評価においては、配合例１の化粧水を４週間塗布することにより、しわグレードが有意に改善していた。また、配合例１の塗布部位と比較配合例１の塗布部位とを比較すると、試験開始日から試験開始４週後の変化量において、配合例１の塗布部位と比較配合例１の塗布部位との間に有意差が認められた。 As shown in Table 2, in the wrinkle grade evaluation by the visual judgment by an expert, the wrinkle grade was significantly improved by applying the lotion of the formulation example 1 for 4 weeks. In addition, comparing the application site of formulation example 1 and the application site of comparative formulation example 1, comparing the application site of formulation example 1 and the application site of comparative formulation example 1 in the amount of change 4 weeks after the test start from the test start date. There was a significant difference between the two.
さらに、表３に示すように、三次元解析においても、配合例１の化粧水を４週間塗布することにより、しわ平均深さ、最大しわ平均深さ、最大しわ最大深さ、総しわ体積、Ra値（粗さ曲線の算術平均粗さ）、およびRy値（粗さ曲線の最大高さ）の６項目に関し、有意に減少していた。そして、上記６項目について、配合例１と比較配合例１とを比較すると、４週間での変化量において、配合例１の塗布部位と比較配合例１の塗布部位との間に有意差が認められた。 Further, as shown in Table 3, also in the three-dimensional analysis, by applying the lotion of formulation example 1 for 4 weeks, the average wrinkle depth, the maximum wrinkle average depth, the maximum wrinkle maximum depth, the total wrinkle volume, The Ra value (arithmetic mean roughness of roughness curve) and the Ry value (maximum height of roughness curve) were significantly decreased for 6 items. When the formulation example 1 and the comparative formulation example 1 are compared with respect to the above 6 items, a significant difference is recognized between the application site of the formulation example 1 and the application site of the comparative formulation example 1 in the change amount over 4 weeks. Was given.
以上の結果より、配合例１（天然物由来成分５種を配合）塗布群では、試験期間前後の比較において、さらには比較配合例１塗布群との比較において、目尻のしわが改善されているものと認められた。 From the above results, in the combination example 1 (containing 5 kinds of natural product-derived components) applied group, wrinkles around the corners of the eyes are improved in comparison before and after the test period and in comparison with the comparison combination example 1 applied group. Was recognized.
〔配合例２〕
下記組成に従い、乳液を常法により製造した。
しわ改善用組成物（製造例１） １．００ｇ
（天然物由来成分５種の合計量 ０．００６０ｇ）
ホホバオイル ４．００ｇ
１，３−ブチレングリコール ３．００ｇ
アルブチン ３．００ｇ
ポリオキシエチレンセチルエーテル（20E.O.） ２．５０ｇ
オリーブオイル ２．００ｇ
スクワラン ２．００ｇ
セタノール ２．００ｇ
モノステアリン酸グリセリル ２．００ｇ
オレイン酸ポリオキシエチレンソルビタン（20E.O.） ２．００ｇ
パラオキシ安息香酸メチル ０．１５ｇ
黄杞エキス ０．１０ｇ
イチョウ葉エキス ０．１０ｇ
オウバクエキス ０．１０ｇ
カミツレエキス ０．１０ｇ
香料 ０．０５ｇ
精製水 残部（全量を１００ｇとする）
[Formulation Example 2]
An emulsion was prepared according to the following composition by a conventional method.
Wrinkle improving composition (Production Example 1) 1.00 g
(Total amount of 5 kinds of ingredients derived from natural products 0.0060 g)
Jojoba oil 4.00g
1,3-butylene glycol 3.00 g
Arbutin 3.00g
Polyoxyethylene cetyl ether (20E.O.) 2.50g
Olive oil 2.00g
Squalane 2.00g
Cetanol 2.00 g
Glyceryl monostearate 2.00 g
Polyoxyethylene sorbitan oleate (20E.O.) 2.00g
Methyl paraoxybenzoate 0.15g
Yellow frost extract 0.10 g
Ginkgo biloba extract 0.10g
Oat extract 0.10g
Chamomile extract 0.10g
Fragrance 0.05g
Purified water balance (total amount is 100 g)
〔配合例３〕
下記組成のクリームを常法により製造した。
しわ改善用組成物（製造例１） ４．００ｇ
（天然物由来成分５種の合計量 ０．０２４０ｇ）
クジンエキス ０．１ｇ
オウゴンエキス ０．１ｇ
流動パラフィン ５．０ｇ
サラシミツロウ ４．０ｇ
スクワラン １０．０ｇ
セタノール ３．０ｇ
ラノリン ２．０ｇ
ステアリン酸 １．０ｇ
オレイン酸ポリオキシエチレンソルビタン（20E.O.） １．５ｇ
モノステアリン酸グリセリル ３．０ｇ
１，３−ブチレングリコール ６．０ｇ
パラオキシ安息香酸メチル １．５ｇ
香料 ０．１ｇ
精製水 残部（全量を１００ｇとする）
[Formulation Example 3]
A cream having the following composition was produced by a conventional method.
Wrinkle improving composition (Production Example 1) 4.00 g
(Total amount of 5 kinds of natural product-derived components 0.0240 g)
Kujin extract 0.1g
Scutellaria extract 0.1 g
Liquid paraffin 5.0 g
White beeswax 4.0g
Squalane 10.0g
Cetanol 3.0g
Lanolin 2.0g
Stearic acid 1.0g
Polyoxyethylene sorbitan oleate (20E.O.) 1.5g
Glyceryl monostearate 3.0 g
1,3-butylene glycol 6.0 g
Methyl paraoxybenzoate 1.5g
Perfume 0.1g
Purified water balance (total amount is 100 g)
〔配合例４〕
下記組成の美容液を常法により製造した。
しわ改善用組成物（製造例１） １．００ｇ
（天然物由来成分５種の合計量 ０．００６０ｇ）
カミツレエキス ０．１ｇ
ニンジンエキス ０．１ｇ
キサンタンガム ０．３ｇ
ヒドロキシエチルセルロース ０．１ｇ
カルボキシビニルポリマー ０．１ｇ
１，３−ブチレングリコール ４．０ｇ
グリセリン ２．０ｇ
水酸化カリウム ０．２５ｇ
香料 ０．０１ｇ
防腐剤（パラオキシ安息香酸メチル） ０．１５ｇ
エタノール ２．０ｇ
精製水 残部（全量を１００ｇとする）
[Formulation Example 4]
A beauty essence having the following composition was produced by a conventional method.
Wrinkle improving composition (Production Example 1) 1.00 g
(Total amount of 5 kinds of ingredients derived from natural products 0.0060 g)
Chamomile extract 0.1g
Carrot extract 0.1g
Xanthan gum 0.3g
Hydroxyethyl cellulose 0.1g
Carboxy vinyl polymer 0.1g
1,3-butylene glycol 4.0 g
Glycerin 2.0g
Potassium hydroxide 0.25g
Fragrance 0.01g
Preservative (methyl paraoxybenzoate) 0.15g
Ethanol 2.0g
Purified water balance (total amount is 100 g)
本発明のしわ改善用組成物は、しわの形成に基づく皮膚の老化症状の改善などに大きく貢献できる。 The composition for improving wrinkles of the present invention can greatly contribute to the improvement of skin aging symptoms due to the formation of wrinkles.
Claims (3)
トウキ抽出物、キンギンカ抽出物、ヨクイニン抽出物および真珠タンパク質加水分解物の４種のうち少なくとも１種と
を組み合わせてなることを特徴とするしわ改善用組成物。 Licorice leaf extract,
A composition for improving wrinkles, which is characterized by being combined with at least one kind of four kinds of Touki extract, Kingfish extract, Yokuinin extract and pearl protein hydrolyzate.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018197701A JP7338842B2 (en) | 2018-10-19 | 2018-10-19 | wrinkle-improving composition and wrinkle-improving skin cosmetic |
| CN201910948150.8A CN111067827B (en) | 2018-10-19 | 2019-10-08 | Composition for improving wrinkles and skin cosmetic for improving wrinkles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018197701A JP7338842B2 (en) | 2018-10-19 | 2018-10-19 | wrinkle-improving composition and wrinkle-improving skin cosmetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020063225A true JP2020063225A (en) | 2020-04-23 |
| JP7338842B2 JP7338842B2 (en) | 2023-09-05 |
Family
ID=70310272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018197701A Active JP7338842B2 (en) | 2018-10-19 | 2018-10-19 | wrinkle-improving composition and wrinkle-improving skin cosmetic |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7338842B2 (en) |
| CN (1) | CN111067827B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220106393A (en) * | 2021-01-22 | 2022-07-29 | 우석대학교 산학협력단 | Cosmetic composition comprising extract of Glycyrrhiza uralensis by-product |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112972361B (en) * | 2021-03-25 | 2022-03-25 | 欧诗漫生物股份有限公司 | Composition, preparation method thereof and anti-aging cosmetic |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0624937A (en) * | 1992-06-29 | 1994-02-01 | Narisu Keshohin:Kk | Mucopolysaccharide fragmentation-inhibiting agent, active oxygen-scavenging agent, antioxidative agent and cosmetic |
| JPH08333275A (en) * | 1995-06-06 | 1996-12-17 | Mikimoto Pharmaceut Co Ltd | Damage curing medicine |
| JP2000191498A (en) * | 1998-12-24 | 2000-07-11 | Maruzen Pharmaceut Co Ltd | Collagen production facilitative agent and preparation for external use for skin |
| JP2006282654A (en) * | 2005-03-09 | 2006-10-19 | Yakult Honsha Co Ltd | Antioxidant |
| JP2006347903A (en) * | 2005-06-14 | 2006-12-28 | Ogawa & Co Ltd | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract |
| JP2006347907A (en) * | 2005-06-14 | 2006-12-28 | Ogawa & Co Ltd | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract |
| JP2012532098A (en) * | 2009-06-30 | 2012-12-13 | 株式会社アモーレパシフィック | Adipocyte differentiation-promoting composition containing ground yolk, licorice, yokoinin, malt, karin, gokahide or kuzu root extract |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004285018A (en) * | 2003-03-25 | 2004-10-14 | Maruzen Pharmaceut Co Ltd | Hair cosmetic |
| RU2414885C1 (en) * | 2009-10-23 | 2011-03-27 | Екатерина Александровна Диброва | Cosmetic preparation based on phitoestrogen biocomplex |
| CN107334696A (en) * | 2017-06-20 | 2017-11-10 | 苏州蔻美新材料有限公司 | A kind of preparation method of skin-moisturizing, skin dew |
-
2018
- 2018-10-19 JP JP2018197701A patent/JP7338842B2/en active Active
-
2019
- 2019-10-08 CN CN201910948150.8A patent/CN111067827B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0624937A (en) * | 1992-06-29 | 1994-02-01 | Narisu Keshohin:Kk | Mucopolysaccharide fragmentation-inhibiting agent, active oxygen-scavenging agent, antioxidative agent and cosmetic |
| JPH08333275A (en) * | 1995-06-06 | 1996-12-17 | Mikimoto Pharmaceut Co Ltd | Damage curing medicine |
| JP2000191498A (en) * | 1998-12-24 | 2000-07-11 | Maruzen Pharmaceut Co Ltd | Collagen production facilitative agent and preparation for external use for skin |
| JP2006282654A (en) * | 2005-03-09 | 2006-10-19 | Yakult Honsha Co Ltd | Antioxidant |
| JP2006347903A (en) * | 2005-06-14 | 2006-12-28 | Ogawa & Co Ltd | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract |
| JP2006347907A (en) * | 2005-06-14 | 2006-12-28 | Ogawa & Co Ltd | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract |
| JP2012532098A (en) * | 2009-06-30 | 2012-12-13 | 株式会社アモーレパシフィック | Adipocyte differentiation-promoting composition containing ground yolk, licorice, yokoinin, malt, karin, gokahide or kuzu root extract |
Non-Patent Citations (3)
| Title |
|---|
| SUPPLE EYE GEL, MINTEL GNPD [ONLINE]， 2012.12，[検索日 2022.06.29], JPN6022027828, ISSN: 0004987992 * |
| TOTALL ALL IN ONE GEL, MINTEL GNPD [ONLINE]， 2016.05，[検索日 2022.06.29], JPN6022027827, ISSN: 0004987991 * |
| VEGETAL MULTI-PERFECTION EYE CREAM, MINTEL GNPD [ONLINE]， 2012.09，[検索日 2022.06.29], JPN6022027829, ISSN: 0004987993 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220106393A (en) * | 2021-01-22 | 2022-07-29 | 우석대학교 산학협력단 | Cosmetic composition comprising extract of Glycyrrhiza uralensis by-product |
| KR102502327B1 (en) | 2021-01-22 | 2023-02-23 | 우석대학교 산학협력단 | Cosmetic composition comprising extract of Glycyrrhiza uralensis by-product |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111067827A (en) | 2020-04-28 |
| JP7338842B2 (en) | 2023-09-05 |
| CN111067827B (en) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100010316A (en) | Cosmetic composition for preventing skin aging | |
| JP2014076957A (en) | Desaccharification agent and skin external preparation | |
| KR102253095B1 (en) | Cosmetic composition for improving acned skin, Manufacturing method thereof and functional cosmetics for improving acned skin containing the same | |
| KR20170137552A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR102062854B1 (en) | Cosmetic composition containing active fractions of Rubus coreanus MIQ root | |
| JP7338842B2 (en) | wrinkle-improving composition and wrinkle-improving skin cosmetic | |
| KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR20170137544A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
| KR20170136911A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170137549A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170136389A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR102198589B1 (en) | Whitening cosmetic composition containing Rhodiola rosea, Selaginella tamariscina, Celosia cristata and Artemisia princeps complex extract and phytol | |
| KR20160003918A (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
| KR20170136933A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| JP6723979B2 (en) | Wrinkle improver | |
| KR20170137559A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170136912A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170136913A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170058546A (en) | Cosmetic Composition for Reducing Skin Wrinkle | |
| KR101736716B1 (en) | Cosmetic composition for skin elasticity and anti-wrinkle comprising plants extract | |
| KR20110094859A (en) | Composition for promoting collagen synthesis having kava extract | |
| KR102628844B1 (en) | Cosmetic composition for anti-oxidation, skin whitening and anti-wrinkle containing a mixed fermentation extracts of Wisteria floribunda flowers, Aralia elata flowers, Camellia japonica leafs and Camellia japonica flowers as effective component | |
| KR102233707B1 (en) | Cosmetic composition comprising natural extract and natural powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210917 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221101 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230515 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230706 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230801 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230817 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7338842 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |